Welcome to our dedicated page for Sol Gel Technolg SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skimming 10-K footnotes for microencapsulation data or tracking when Sol Gel’s executives sell shares can take hours. Clinical-stage dermatology companies like Sol Gel Technologies file dense reports packed with trial endpoints, FDA correspondence, and milestone payment clauses that are easy to miss.
Our platform turns that complexity into clarity. Stock Titan’s AI reads every Sol Gel Technologies annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events explained, then serves up plain-English takeaways—no pharmacology PhD required. Need Sol Gel Technologies insider trading Form 4 transactions or real-time alerts on Sol Gel Technologies Form 4 insider transactions real-time? We surface them seconds after they hit EDGAR. You’ll also find concise notes on R&D spend trends, partnership royalties, and how each pipeline update affects future cash burn, all inside our Sol Gel Technologies earnings report filing analysis.
Whether you’re monitoring Sol Gel Technologies proxy statement executive compensation ahead of a vote, comparing segment results across filings, or understanding Sol Gel Technologies SEC documents with AI for a rapid diligence check, every disclosure is here. Filter by form type, download exhibits, or jump straight to AI-powered summaries that highlight acne and rosacea trial milestones. From Sol Gel Technologies executive stock transactions Form 4 to a Sol Gel Technologies annual report 10-K simplified overview, you get the insight you need—faster than reading 200 pages of regulatory prose.
Opaleye Management Inc. reported open market purchases of Sol-Gel Technologies Ltd. (SLGL) ordinary shares. On 11/24/2025, an affiliated fund bought 6 ordinary shares at $35.5 per share, and on 11/26/2025 it bought another 943 shares at a weighted average price of $40.00. Following these transactions, the fund is shown as beneficially owning 364,100 Sol-Gel ordinary shares, with an additional 10,000 shares held in a separately managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and the managed account and disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) director Opaleye Management Inc. reported buying additional ordinary shares. On 11/20/2025, an affiliated fund purchased 5,784 ordinary shares at a weighted average price of $35.8305 per share in multiple trades within a price range of $35.132 to $36.10. After this transaction, Opaleye Management Inc. reports indirect beneficial ownership of 363,151 ordinary shares through Opaleye, L.P. and 10,000 ordinary shares through a separately managed account. The firm states it may be deemed to beneficially own these securities as investment manager and portfolio manager, while disclaiming beneficial ownership beyond its economic interest.
Sol-Gel Technologies Ltd. (SLGL) submitted a Form 6-K reporting that it issued a press release on November 20, 2025 announcing its financial results for the quarter ended September 30, 2025. The filing mainly serves to furnish this press release to investors.
Most of the press release, identified as Exhibit 99.1 (other than the two paragraphs immediately preceding the heading “Financial Results for the Third Quarter 2025”), is incorporated by reference into the company’s Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).
Sol-Gel Technologies Ltd. (SLGL)
Sol-Gel Technologies Ltd. furnished a Notice of its 2025 Annual General Meeting and an accompanying proxy statement, together with a proxy card for shareholders of record as of September 29, 2025. The materials are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, ensuring the proxy disclosures are available to holders eligible to vote and to support related securities registrations. This filing supplies the formal voting materials shareholders need to review meeting matters and to submit proxies ahead of the meeting.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of 139,386 ordinary shares of Sol-Gel Technologies Ltd (SLGL), representing 5.00% of the class based on 2,785,787 shares outstanding. The shares are held by the Fund with voting and dispositive power shared among the reporting persons; no sole voting or dispositive power is reported. The filing states the stake was not acquired to change or influence control of the issuer and includes a joint filing agreement signed by James Silverman.
Sol-Gel Technologies Ltd. submitted a Form 6-K reporting two exhibits: a press release dated August 15, 2025 and unaudited condensed consolidated financial statements as of June 30, 2025 covering the three- and six-month periods ended June 30, 2025. The filing amends and restates the incorporation-by-reference language so that Exhibit 99.1 (except for four paragraphs immediately preceding the financial-results heading) and Exhibit 99.2 are incorporated into the company’s registration statements on Forms S-8 and F-3. The report is signed by the Chief Financial Officer, indicating the exhibits are being furnished to the SEC and made available to investors and registrants relying on the referenced registration statements.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
